BPA study documents available
This article was originally published in The Tan Sheet
Executive SummaryFDA solicits public comment on a series of documents reviewing studies on the toxicological effects of bisphenol A. In a Federal Register notice prepared for April 5 publication, the agency notes the documents detail the Center for Food Safety and Applied Nutrition's assessment of low-dose BPA studies and offer an updated dietary exposure estimate for food contact uses of BPA in packaging for infant formula and other products (1"The Tan Sheet" Jan. 25, 2010). FDA will accept comments on the documents through June 4
You may also be interested in...
For providers and medtech manufacturers alike, the decade ahead will be a time of coming to terms with digital technologies and integrating new methods of payment. Quality of service delivery remains the market entry criterion, but companies will have to adapt to evolving health care delivery models. The stakes are implausibly high. Will they be able to capitalize on the changes in a market that is more competitive and unpredictable than ever?
Crystal ball gazing is a tricky, sometimes futile, endeavor. No one knows what the future holds, but there are consistent scenarios emerging that are being debated by industry leaders as they try to foretell and outsmart key market catalysts expected to ripple across the biopharma sector in 2020. With insights from executives, investors and consultancies, as well as our own experts, In Vivo can paint a picture of biopharma wins and woes expected in the new year and new decade.
Janssen’s hemato-oncology success rolls on with impressive new overall survival data